Transamniotic Delivery of Hematopoietic Stem Cells Genetically Modified to Carry a Human Hemoglobin Subunit Beta Gene (HBB) in a Healthy Rodent Model

Space: StayCurrentMD Author: Kamila Moskowitzova, Emily M. Scire, Ina Kycia, Tanya T. Dang, Beatriz S. Bechara, Eva Zacharakis, Ayaka Aihara, Yash V. Shroff, David Zurakowski, Dario O. Fauza Published:

Author / Expert

Kamila Moskowitzova, Emily M. Scire, Ina Kycia, Tanya T. Dang, Beatriz S. Bechara, Eva Zacharakis, Ayaka Aihara, Yash V. Shroff, David Zurakowski, Dario O. Fauza

Topic overview

We sought to determine whether transamniotic stem cell therapy (TRASCET) could be a viable alternative for the fetal administration of genetically modified hematopoietic stem cells (HSCs) carrying a human hemoglobin subunit beta gene (hHBB) in a healthy syngeneic rat model.

Keywords

Hashtags

1 Views
0 Comments

Comments

Loading comments...